Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
The Dixie Group, Inc. Q4 2025 Earnings Call - Gained Carpet Market Share While Cutting Costs and Eating Tariffs
Dixie delivered a defensive quarter: sales slipped modestly, yet margins improved materially as the company squeezed costs and leaned on reshoring investments. Net sales for Q4 fell 1.4% year over yea...
- Net sales Q4 2025 of $63.487 million were down 1.4% versus Q4 2024, full year 2025 sales of $257.429 million were down 2.9% year over year.
- Net loss improved: Q4 2025 loss of $3.0 million versus $7.198 million a year ago, full year 2025 net loss of $7.615 million versus $13.0 million in 2024.
- Gross margins rose to 27% for both the quarter and full year 2025, up from 21.7% in the prior year quarter and 24.7% for FY 2024, driven by cost reductions and profit improvement initiatives.
- +12 more takeaways
Stran & Company FY2025 Earnings Call - 40.6% Revenue Jump and Break-Even EBITDA, Tariffs Still Pinch Margins
Stran delivered a sharp growth year in FY2025, reporting $116.2 million in revenue, up 40.6% year over year, driven by a full-year consolidation of the Gander Group assets and 12.9% organic expansion ...
- Revenue grew 40.6% to $116.2 million in FY2025, up from $82.7 million in 2024.
- Organic growth in the core promotional products business was 12.9%, indicating healthy underlying demand from existing clients.
- Stran recorded $34.2 million in gross profit, equal to 29.5% of sales, down from 31.2% last year due to mix and the consolidated loyalty business.
- +13 more takeaways
WhiteFiber, Inc. Q4 2025 Earnings Call - Retrofit Speed and a De-risked NC1 Backed by an Investment-Grade Offtaker
WhiteFiber leaned into its retrofit-first playbook in Q4, converting Montreal 3 from an industrial factory into a live data center in roughly six months and bringing on Cerebras as a tenant. The compa...
- Completed IPO in 2025 and set up standalone public-company reporting and governance.
- Montreal 3 delivered in Q4 2025 via a retrofit of an industrial factory in about six months, supporting Cerebras as a colocation tenant.
- Company is exercising a purchase option on Montreal 3 for approximately CAD 24 million, which will cut lease payments by about CAD 3.1 million annually.
- +12 more takeaways
BRP Inc. Q4 FY2026 Earnings Call - Inventory Right-Sized and New Models Fuel Share Gains, Yet Tariffs and Oil Pressure Narrow Margins
BRP closed fiscal 2026 with a clean finish, reporting CAD 8.4 billion in revenue, normalized EBITDA of CAD 1.1 billion and more than CAD 900 million of free cash flow. Management says dealer inventori...
- New CEO Denis Mansueto has been in the role two months, praises BRP’s product pipeline and culture, and plans no immediate strategic overhaul while preparing a longer term plan.
- FY2026 results beat guidance: revenue CAD 8.4 billion, normalized EBITDA CAD 1.1 billion, normalized EPS CAD 5.21, and free cash flow above CAD 900 million.
- Q4 revenue grew 16% to about CAD 2.5 billion; normalized EBITDA rose 47% to CAD 364 million and normalized EPS doubled to CAD 2.21 in the quarter.
- +12 more takeaways
Innate Pharma Full Year 2025 Earnings Call - IPH4502 shows post-PADCEV clinical activity, lacutamab Phase III cleared but financing needed
Innate Pharma doubled down on three priority assets, signalling a leaner company focused on late-stage value. The big technical wins are clear: FDA cleared the TELLOMAK 3 protocol for lacutamab in CTC...
- Company strategy: Innate has prioritized three high-value programs, lacutamab, IPH4502, and monalizumab, and is trimming organization costs to focus capital on late-stage development and ADC platform work.
- Lacutamab regulatory progress: FDA cleared the TELLOMAK 3 Phase III protocol for CTCL, with planned initiation in the second half of 2026, contingent on securing financing.
- TELLOMAK 3 design: Two independent randomized cohorts for Sézary syndrome and mycosis fungoides, primary endpoint is PFS by blinded independent central review, secondary endpoints include OS for SS and QoL/pruritus for MF.
- +13 more takeaways
Shoe Carnival Fourth Quarter 2025 Earnings Call - EPS Guidance Cut as Tariff Timing and Rebanners Pressure Margins
Shoe Carnival closed fiscal 2025 with clean balance sheet and solid margin trends, but management is guiding to a meaningful EPS step down in fiscal 2026 driven by a timing mismatch between pre-tariff...
- Fiscal 2025 EPS was $1.90, beating consensus, with fourth quarter EPS of $0.33, modestly above expectations.
- Management guided fiscal 2026 EPS to $1.40 to $1.60, excluding CEO transition costs, a sizable step down from $1.90 in fiscal 2025.
- Primary driver of the 2026 earnings step down is gross margin compression, guided to approximately 34%, roughly 260 basis points below fiscal 2025, driven by tariff timing, the non-recurrence of temporary pricing benefits, and promotional markdowns to clear inventory.
- +12 more takeaways
KNOT Offshore Partners Q4 2025 Earnings Call - Tightening Shuttle Tanker Market, $929M Backlog and Strengthening Balance Sheet
KNOT Offshore reported a quarter that looks better on the inside than the headline loss suggests. Revenues were $96.5 million, adjusted EBITDA $59.3 million, and underlying operating income would have...
- Revenues: $96.5 million in Q4 2025.
- Adjusted EBITDA: $59.3 million for the quarter.
- Reported operating income: $8.4 million; operating income excluding Bodil Knutsen impairment: $28.6 million.
- +17 more takeaways
The Lovesac Company Q4 FY2026 Earnings Call - Made in America Push, Snug Growth and Digital Pivot Offset Tariff Headwinds
Lovesac closed fiscal 2026 with modest top-line growth and a sharpened strategic playbook. Q4 net sales rose 2.7% and full-year revenue reached $697.1 million, helped by a 12.3% surge in internet sale...
- Q4 net sales rose 2.7% to $248.0 million, full-year revenue was $697.1 million, up from $680.6 million in FY2025.
- Internet sales grew 12.3% in Q4 to $79.2 million, reflecting early benefits from new digital leadership and site upgrades.
- Omni-channel comparable net sales were positive in Q4 and for the full year, while the broader category remained in decline.
- +16 more takeaways
Lucid Diagnostics Fourth Quarter 2025 Earnings Call - VA Contract at Medicare Rate and Medicare Coverage Imminent
Lucid closed 2025 with clear commercial momentum, a strategic VA win, and Medicare coverage looming. Test volume rose to 3,664 in Q4, a 29% sequential increase, producing $1.5 million of recognized re...
- Q4 volume was 3,664 EsoGuard tests, a 29% sequential increase from Q3 2025.
- Lucid recognized $1.5 million of revenue in Q4, on approximately $9 million of billable claims; recognized revenue equals about 17% of billed value for the quarter.
- Company won a U.S. Department of Veterans Affairs Federal Supply Schedule contract for EsoGuard, priced aligned with the Medicare rate of $1,938.
- +12 more takeaways
Lumexa Imaging Fourth Quarter 2025 Earnings Call - IPO Deleveraged Balance Sheet as EBITDA and Advanced Imaging Accelerate
Lumexa closed its first year as a public company with a solid Q4, reporting $267.7 million in revenue, up 7.9% year over year, and adjusted EBITDA of $63.8 million, up 18.6%, for a 23.8% adjusted EBIT...
- Q4 revenue $267.7 million, up 7.9% year over year; adjusted EBITDA $63.8 million, up 18.6%, adjusted EBITDA margin 23.8%.
- Full-year 2025 revenue $1.023 billion (+7.8% YoY); adjusted EBITDA $230.2 million (+14.6%), margin 22.5%.
- System-wide activity: 1.4 million advanced imaging exams in Q4, up 7.7% year over year; system-wide revenue growth was 10.6% in Q4.
- +12 more takeaways